4DMedical (4DX) Stock Price, Fundamentals & Analysis

What 4DX does

4DMedical (4DX) is a healthcare stock listed on the ASX in the Medical Devices industry. The company develops non-invasive respiratory imaging solutions, including CT:VQ, a post-processing technology for lung scans; CAC, a cardiothoracic risk assessment tool; and XV Scanner, a lung function scanner. It also offers software such as CT LVAS for regional lung function imaging, LDAf based on its patented Parametric Response Mapping (PRM) technology, and PHA Analysis, a fully-automated imaging solution. 4DMedical has a partnership with AstraZeneca to expand a lung health screening program and a contractual engagement with GlaxoSmithKline to provide quantitative lung imaging analytics for pulmonary drug development and clinical research. The company, incorporated in 2012 and headquartered in Carlton, Australia, employs 181 people.

Key numbers explained

• 4 AUD is the latest price per share — the amount you would pay for one share in the market right now.
• -2.44% is the price change today — the stock is down by that percentage so far on the trading day.
• 2.41 mld. AUD is the market capitalisation — the total value of all outstanding shares, calculated as share price multiplied by the number of shares.
• The forward P/E ratio of -205.1 is based on expected earnings; a negative figure means the market expects a loss, so the ratio is not meaningful as a valuation multiple in the usual way.
• Earnings per share (trailing 12 months) of -0.34 AUD shows the company lost money on a per-share basis over the last twelve months.
• 0% dividend yield and 0% share of earnings paid out as dividends mean 4DMedical does not currently pay a cash dividend to shareholders.
• 1.95 beta indicates the stock tends to move about twice as much as the broader market in percentage terms — higher volatility both up and down.
• 122.2% price change over the last 52 weeks shows the share price has more than doubled from its level a year ago, even though the low of 1.4 and high of 7.55 show a wide range during that period.
• 42.3% revenue growth (year over year) and 7.06 mil. AUD trailing 12-month revenue indicate the company is growing its top line quickly from a small base.
• -735.1% operating margin and -174.4% return on equity highlight that the company is currently operating at a significant loss relative to its revenue and shareholders' equity.
• 105.9% debt-to-equity ratio means the company has slightly more debt than equity on its balance sheet.
• 14.04 price-to-book compares the market price to the book value of its assets; a high multiple can reflect expectations about future earnings or intangible assets.

What to watch

• 4DMedical operates in a regulated healthcare environment where product approvals, clinical evidence, and reimbursement decisions can affect demand for its imaging solutions.
• As a small-cap stock on the ASX, liquidity and trading volume can be lower than large-cap peers like ResMed (RMD), which may affect how easily positions can be entered or exited.
• The company's reliance on partnerships with large pharmaceutical and medical companies means commercial progress can depend on the timing and success of those collaborations.
• Investors often compare medical-device stocks with peers such as Cochlear (COH) or Ansell (ANN) to gauge sector valuation and growth expectations.
• The wide 52-week range (1.4 to 7.55) and high beta (1.95) suggest the share price can be volatile, so position sizing and risk tolerance are relevant considerations.
• Revenue growth of 42.3% is notable, but because the base is small (7.06 mil. AUD), sustaining that rate requires continued product adoption and expansion.